02252 MEDBOT-B
- 15.840
- +0.800+5.32%
MEDBOT-B News
Minimally invasive robot-B (02252.HK): Tumai's endoscopic surgical robot obtained EU CE certification
Minimally invasive robot-B (02252.HK) announced that the Tumai endoscopic surgical robot system (Tumai) independently developed by the Group has successfully obtained EU CE certification. It can be used in urology, general surgery, thoracic surgery, and gynecological endoscopic surgery, making it currently the first and only domestic endoscopic surgery robot to obtain CE certification from the European Union.
Hong Kong Stock Concept Tracking | Favorable Policies Drive Continued Demand Expansion, Domestic Medical Device Companies Usher in Development Opportunities (with concept stocks)
Guodu Securities believes that overall, as the medical sector implements equipment renewal actions, it will drive the release of domestic demand for medical equipment.
Baili Tianheng and Shenzhou Cell turned losses into profits! Many biomedical companies on the Science and Technology Innovation Board ushered in a “good start” in Q1
In the first quarter of 2024, many parts of the country successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to continuously optimize the biomedical innovation environment.
微創機器人-B：2023年度報告
Minimally Invasive Robot-B (02252) announced annual results. Shareholders' losses of 1,012 billion yuan narrowed 11.2% year-on-year
Minimally Invasive Robot-B (02252) announced its annual results for the year ended December 31, 2023. The group...
MEDBOT-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Changes in Hong Kong stocks | Medical device stocks rose higher in the afternoon, and mining affected the industry's high-value consumables business growth expectations this year generally improved
Medical device stocks rose in the afternoon. As of press release, Weigao shares (01066) rose 9.25% to HK$5.08; Elken Healthcare (01,789) rose 4.35% to HK$4.08; and minimally invasive robot-B (02252) rose 1.91% to HK$13.88.
Minimally Invasive Robot-B (02252.HK) plans to hold a board meeting on March 27 to consider and approve the annual results
Gelonghui March 15 | Minimally Invasive Robot-B (02252.HK) announced that the company will hold a board meeting on March 27, 2024 (Wednesday) to consider and approve, including the Group's annual results for the year ended December 31, 2023, the proposed final dividend (if any), and other matters.
MEDBOT-B: DATE OF BOARD MEETING
Guojin Securities: Medical equipment updates are expected to accelerate demand for high-end innovative medical equipment is expected to be released
It is recommended to focus on segments such as surgical robotics, endoscopes, ultrasound, and ICU equipment.
Hong Kong Stock Concept Tracking | Policies Promote Large-scale Equipment Renewal Agencies to Pay Attention to Medical Equipment Procurement Needs (with concept stocks)
On March 1, the Executive Meeting of the State Council reviewed and approved the “Action Plan to Promote Large-scale Equipment Renewal and Trade-in of Consumer Goods”, which proposed “promoting the orderly upgrading of equipment, transportation equipment, and old agricultural machinery, education and medical equipment in key industries.” The equipment update focuses on the field of “building diplomatic relations between workers and agriculture, education, culture and medicine”. The investment scale was about 6 trillion yuan in '27, with an additional investment of about 300 billion dollars every year, focusing on key industries such as metals, chemicals, building materials, electricity, machinery, transportation, textiles, and electronics. Financial support includes subsidies, tax incentives, and reloan interest rates. According to “Chinese Medical Devices
Changes in Hong Kong stocks | Minimally Invasive Robot-B (02252) rose nearly 20% in the intraday period, annual revenue increased 3.5 times, Tumai Robotics completed its first overseas operation
Minimally invasive robot-B (02252) rose nearly 20% in the intraday period. As of press release, it was up 15.7% to HK$15.18, with a turnover of HK$6.086 million.
Changes in Hong Kong stocks | Minimally Invasive Robot-B (02252) rose more than 16%, and annual revenue is expected to increase by more than 350% year-on-year, and losses narrow to a maximum of 1.05 billion yuan
Minimally invasive robot-B (02252) rose more than 16%. As of press release, it rose 12.92% to HK$16.08, with a turnover of HK$21.578 million.
Changes in Hong Kong stocks | Minimally Invasive Robot-B (02252) fell by more than 3% and is expected to have a net loss of no more than 1.05 billion yuan last year
Minimally invasive robot-B (02252) fell by more than 3%. As of press release, it was down 3.09% to HK$13.8 million, with a turnover of HK$5.87,800.
Announcement Highlights | NIO's Q4 revenue increased 6.5% year on year to 17.103 billion yuan; Great Wall Motor's February sales increased 4.12% year on year
China Electric Power's combined total electricity sales volume in January was 10.3482 million megawatt-hours, an increase of 41.15% over the previous year; Shanghai Pharmaceutical: Norepinephrine bitartrate injection passed the generic drug consistency evaluation.
Minimally Invasive Robot-B (02252.HK) expects revenue growth of more than 350% year-on-year in 2023
Gelonghui, March 5 | Minimally Invasive Robot-B (02252.HK) announced that in the face of a complex and changing external environment, in 2023, the Group will adhere to a business-focused strategy with the primary goal of promoting sustainable business growth, and continuously and thoroughly improve operational efficiency. With extensive multi-track layout, excellent product performance and industry-leading commercialization strength, the Group's many listed products have made significant progress in domestic commercialization breakthroughs and global expansion. The Board of Directors expects the company's revenue for the year ended December 31, 2023 to increase more than year-on-year over the year ended December 31, 2022
Financial Services Association Venture Capital Connect: In February, the domestic medical sector raised 4.1 billion yuan, down 42% month-on-month, with the highest amount of financing for innovative drugs
In February 2024, there were 80 private equity financing incidents in the domestic healthcare sector, a decrease of 27% from the previous month; the total amount of disclosed financing was about 4,066 billion yuan, a decrease of 42% from the previous month.
Read it in one picture | The list of Hong Kong stock bulls and bears for January has been released! The popularity of central and state-owned enterprises has revived, and China Alcoa International has risen more than 20% per month
The agency believes that with an extremely high margin of safety+expectation of continuous improvement in ROE+policy catalytic assessment of market value, a new round of value revaluation by central enterprises is worth looking forward to.
Highlights of the morning brokerage meeting: Focus on opportunities to increase the localization rate of medical devices
At today's brokerage morning meeting, CICC believes that it is concerned about opportunities to increase the localization rate of medical devices; CITIC Construction Investment pointed out that the future of the cross-border e-commerce industry has great potential; and Guotai Junan said that it is concerned about undervalued consumption of blue-chip stocks.
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
Analysis
Price Target
No Data
